Evidence map›Paper›PMID 29565423›Full record

Trial reportGenetics in medicine : official journal of the American College of Medical Genetics2018

Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial.

Kurt D Christensen, Jason L Vassy, Kathryn A Phillips, Carrie L Blout, Danielle R Azzariti, Christine Y Lu, Jill O Robinson, Kaitlyn Lee, Michael P Douglas, Jennifer M Yeh and 7 more

2 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Genetics in medicine : official journal of the American College of Medical Genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04196374 nacompletednot on this mapstarted 2021, after this paper: background citation

Return of Genomic Results and Aggregate Penetrance in Population-Based Cohorts

TypeinterventionalSponsorBrigham and Women's HospitalRan2021 to 2025Enrolled7,603ConditionsSeemingly Healthy, Genetic Predisposition to DiseaseArmsGenomic Sequencing
NCT04331535 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Pragmatic Randomized Trial of Polygenic Risk Scoring for Common Diseases in Primary Care

TypeinterventionalSponsorBoston VA Research Institute, Inc.Ran2020 to 2025Enrolled1,076ConditionsCoronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal CancerArmsPolygenic risk score (PRS)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Delivering genomic medicine in the United Kingdom National Health Service: a systematic review and narrative synthesis.Genetics in medicine : official journal of the American College of Medical Genetics · 2019
    Pooled it
  3. Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020
    Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. A Cost-Consequence Analysis of PreemptiveJournal of personalized medicine · 2021
    Article
  13. Article
  14. Article
  15. Identification of clinically actionable variants from genome sequencing of families with congenital heart disease.Genetics in medicine : official journal of the American College of Medical Genetics · 2019
    Article
  16. Article
  17. Integrating Genomics into Healthcare: A Global Responsibility.American journal of human genetics · 2019
    Article
  18. Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kurt D ChristensenDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. kchristensen@bwh.harvard.edu.
Jason L VassyDepartment of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Kathryn A PhillipsDepartment of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco, California, USA.
Carrie L BloutDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Danielle R AzzaritiPartners HealthCare Laboratory for Molecular Medicine, Cambridge, Massachusetts, USA.
Christine Y LuDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Jill O RobinsonCenter for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.
Kaitlyn LeeCenter for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.
Michael P DouglasDepartment of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco, California, USA.
Jennifer M YehDepartment of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Kalotina MachiniPartners HealthCare Laboratory for Molecular Medicine, Cambridge, Massachusetts, USA.
Natasha K StoutDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Heidi L RehmPartners HealthCare Laboratory for Molecular Medicine, Cambridge, Massachusetts, USA.
Amy L McGuireCenter for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.
Robert C GreenDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Dmitry DukhovnyDepartment of Pediatrics, Oregon Health & Science University, Portland, Oregon, USA.
MedSeq Project

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Integration of Whole Genome Sequencing into Clinical MedicineU01HG006500 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C. · 2012 to 2016
$11.5M
Harvard Clinical and Translational Science CenterKL2TR001100 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$8.5M
Risk-Benefit Trade-Offs for Whole Genome SequencingR01HG007063 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2013 to 2016
$2.5M
Cost-effectiveness of Whole Genome Sequencing of Healthy AdultsK01HG009173 · NHGRI · HARVARD PILGRIM HEALTH CARE, INC. · PI CHRISTENSEN, KURT DEREK · 2016 to 2020
$626k
Clinical safety and efficacy of pharmacogenetics in Veteran careIK2CX001262 · VA · VA BOSTON HEALTH CARE SYSTEM · PI VASSY, JASON L · 2016 to 2021
–
CSRD VA IK2 CX001262NCATS NIH HHS KL2 TR001100NCATS NIH HHS UL1 TR001102NHGRI NIH HHS K01 HG009173NHGRI NIH HHS R01 HG007063NHGRI NIH HHS U01 HG006500
6 · The paper itself

Abstract

purposeGreat uncertainty exists about the costs associated with whole-genome sequencing (WGS).

methodsOne hundred cardiology patients with cardiomyopathy diagnoses and 100 ostensibly healthy primary care patients were randomized to receive a family-history report alone or with a WGS report. Cardiology patients also reviewed prior genetic test results. WGS costs were estimated by tracking resource use and staff time. Downstream costs were estimated by identifying services in administrative data, medical records, and patient surveys for 6 months.

resultsThe incremental cost per patient of WGS testing was $5,098 in cardiology settings and $5,073 in primary care settings compared with family history alone. Mean 6-month downstream costs did not differ statistically between the control and WGS arms in either setting (cardiology: difference = -$1,560, 95% confidence interval -$7,558 to $3,866, p = 0.36; primary care: difference = $681, 95% confidence interval -$884 to $2,171, p = 0.70). Scenario analyses showed the cost reduction of omitting or limiting the types of secondary findings was less than $69 and $182 per patient in cardiology and primary care, respectively.

conclusionShort-term costs of WGS were driven by the costs of sequencing and interpretation rather than downstream health care. Disclosing additional types of secondary findings has a limited cost impact following disclosure.

Indexed as

CardiologyCost-Benefit AnalysisFemaleGenetic TestingHumansMalePilot ProjectsPrimary Health CareWhole Genome Sequencingcardiologycostseconomicsprimary carewhole-genome sequencing

Identifiers

PMID29565423
PMCPMC6151171

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.